Clinical Trial Update: Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite) [Phase 3]

View source ↗

Summary

Phase 3 long-term study of EN3835 (CCH-aaes) in edematous fibrosclerotic panniculopathy (cellulite) completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cellulite
• Edematous Fibrosclerotic Panniculopathy

Drugs mentioned

• EN3835 (CCH-aaes) (collagenase clostridium histolyticum-aaes)

Snippet

Sponsor: Endo Pharmaceuticals | Conditions: Edematous Fibrosclerotic Panniculopathy, Cellulite | Phase 3 | Status: COMPLETED | Results posted: 2023-09-08